CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-04 | MPM BioVentures 2014, L.P. 10% owner | Conversion · Series B Preferred Stock | −6,621,546 | 0 | ||
| 2021-05-04 | GADICKE ANSBERT 10% owner | Conversion | +4,477,742 | 4,939,150 | ||
| 2021-05-04 | GADICKE ANSBERT 10% owner | Conversion | +1,488,033 | 6,427,183 | ||
| 2021-05-04 | GADICKE ANSBERT 10% owner | Purchase | +245,000 | $16.00 | $3.9M | 6,672,183 |
| 2021-05-04 | GADICKE ANSBERT 10% owner | Conversion · Series A Preferred Stock | −38,817,998 | 0 | ||
| 2021-05-04 | GADICKE ANSBERT 10% owner | Conversion · Series B Preferred Stock | −12,899,925 | 0 | ||
| 2021-05-04 | EVNIN LUKE Director | Conversion | +2,756,073 | 3,217,481 | ||
| 2021-05-04 | EVNIN LUKE Director | Conversion | +915,892 | 4,133,373 | ||
| 2021-05-04 | EVNIN LUKE Director | Purchase | +150,799 | $16.00 | $2.4M | 4,284,172 |
| 2021-05-04 | EVNIN LUKE Director | Conversion · Series A Preferred Stock | −23,892,677 | 0 | ||
| 2021-05-04 | EVNIN LUKE Director | Conversion · Series B Preferred Stock | −7,939,970 | 0 | ||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,915,546 | 1,915,546 | ||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +1,609,212 | $16.00 | $25.7M | 3,524,758 |
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +338,037 | 338,037 | ||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +105,788 | $16.00 | $1.7M | 443,825 |
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −16,606,068 | 0 | ||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series B Preferred Stock | −2,930,482 | 0 | ||
| 2021-05-04 | HBM Healthcare Investments (Cayman) Ltd. 10% owner | Conversion | +625,995 | 625,995 | ||
| 2021-05-04 | HBM Healthcare Investments (Cayman) Ltd. 10% owner | Conversion · Series B Preferred Stock | +5,426,819 | 0 | ||
| 2021-05-04 | Flynn James E 10% owner | Conversion | +1,752,787 | 1,752,787 |
Page 14 of 17 · 335 trades